科微学术

生物工程学报

2025年5月8日 12:20 星期四
首页 > 过刊浏览>2023年第39卷第1期 >132-148. DOI:10.13345/j.cjb.220420
PDF HTML阅读 XML下载 导出引用 引用提醒
溴结构域蛋白4的结构和功能及其抑制剂在肿瘤研究中的应用
作者:
基金项目:

广东省大学生创新创业训练项目(S202012121094)


Advances of structure and mechanisms of bromodomain- containing protein 4 and its related research in tumors
Author:
  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [62]
    • |
  • 相似文献 [20]
    • | | |
  • 文章评论
    摘要:

    溴结构域和超末端结构域(bromodomain and extraterminal domain, Bet)家族是表观基因组的调节因子，也是肿瘤细胞生存所依赖的肿瘤相关基因表达的关键驱动因子。溴结构域蛋白4 (bromodomain-containing protein 4, Brd4)是溴域和端外蛋白家族中的一员，通常识别乙酰化组蛋白，并定位于目的基因的启动子或增强子区域，启动并维持肿瘤相关基因的表达。Brd4与多种转录因子调控和染色质修饰密切相关，并参与DNA损伤修复、维持端粒功能，从而维持肿瘤细胞的存活。本文围绕Brd4蛋白的结构、功能及其抑制剂在肿瘤研究中的应用进行综述。

    Abstract:

    The bromodomain and extraterminal domain (Bet) family are the regulators of the epigenome and also the pivotal driving factors for the expression of tumor related genes that tumor cells depend on for survival and proliferation. Bromodomain-containing protein 4 (Brd4) is a member of the Bet protein family. Generally, Brd4 identifies acetylated histones and binds to the promoter or enhancer region of target genes to initiate and maintain expression of tumor related genes. Brd4 is closely related to the regulation of multiple transcription factors and chromatin modification and is involved in DNA damage repair and maintenance of telomere function, thus maintaining the survival of tumor cells. This review summarizes the structure and function of Brd4 protein and the application of its inhibitors in tumor research.

    参考文献
    [1] 邱海波, 曹素梅, 徐瑞华. 基于2020年全球流行病学数据分析中国癌症发病率、死亡率和负担的时间趋势及与美国和英国数据的比较[J]. 癌症, 2022, 41(4):165-177. QIU HB, CAO SM, XU RH. Analysis of the time trend of cancer incidence, mortality and burden in China based on the global epidemiological data in 2020 and comparison with the data of the United States and Britain[J]. Chinese Journal of Cancer, 2022, 41(4):165-177(in Chinese).
    [2] AYGUN D, BJORNSSON HT. Clinical epigenetics:a primer for the practitioner[J]. Developmental Medicine and Child Neurology, 2020, 62(2):192-200.
    [3] ILANGO S, PAITAL B, JAYACHANDRAN P, PADMA P, NIRMALADEVI R. Epigenetic alterations in cancer[J]. Frontiers in Bioscience:Landmark Edition, 2020, 25(6):1058-1109.
    [4] STATHIS A, BERTONI F. BET proteins as targets for anticancer treatment[J]. Cancer Discovery, 2018, 8(1):24-36.
    [5] DONATI B, LORENZINI E, CIARROCCHI A. BRD4 and cancer:going beyond transcriptional regulation[J]. Molecular Cancer, 2018, 17(1):164.
    [6] VOLLMUTH F, BLANKENFELDT W, GEYER M. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution[J]. Journal of Biological Chemistry, 2009, 284(52):36547-36556.
    [7] FERRI E, PETOSA C, MCKENNA CE. Bromodomains:structure, function and pharmacology of inhibition[J]. Biochemical Pharmacology, 2016, 106:1-18.
    [8] CHIANG CM. Brd4 engagement from chromatin targeting to transcriptional regulation:selective contact with acetylated histone H3 and H4[J]. F1000 Biology Reports, 2009, 1:98.
    [9] ROE JS, VAKOC CR. The essential transcriptional function of BRD4 in acute myeloid leukemia[J]. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81:61-66.
    [10] ZHANG XH, LEE HC, SHIRAZI F, BALADANDAYUTHAPANI V, LIN H, KUIATSE I, WANG H, JONES RJ, BERKOVA Z, SINGH RK, LU J, QIAN YM, RAINA K, COLEMAN KG, CREWS CM, LI BZ, WANG HH, HAILEMICHAEL Y, THOMAS SK, WANG ZQ, et al. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma[J]. Leukemia, 2018, 32(10):2224-2239.
    [11] ALI A, SHAFARIN J, ABU JABAL R, ALJABI N, HAMAD M, SUALEH MUHAMMAD J, UNNIKANNAN H, HAMAD M. Ferritin heavy chain (FTH1) exerts significant antigrowth effects in breast cancer cells by inhibiting the expression of c-MYC[J]. FEBS Open Bio, 2021, 11(11):3101-3114.
    [12] WU SY, LEE CF, LAI HT, YU CT, LEE JE, ZUO H, TSAI SY, TSAI MJ, GE K, WAN YH, CHIANG CM. Opposing functions of BRD4 isoforms in breast cancer[J]. Molecular Cell, 2020, 78(6):1114-1132.e10
    [13] SHU SK, LIN CY, HE HH, WITWICKI RM, TABASSUM DP, ROBERTS JM, JANISZEWSKA M, HUH SJ, LIANG Y, RYAN J, DOHERTY E, MOHAMMED H, GUO H, STOVER DG, EKRAM MB, PELUFFO G, BROWN J, DSANTOS C, KROP IE, DILLON D. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer[J]. Nature, 2016, 529(7586):413-417.
    [14] NOBLEJAS LÓPEZ MDM, NIETO-JIMÉNEZ C, GALÁN-MOYA EM, BURGOS M, MONTERO JC, GÓMEZ-JUÁREZ M, PANDIELLA A, OCAÑA A. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer[J]. Annals of Oncology, 2019, 30:v101.
    [15] JING X, SHAO S, ZHANG YJ, LUO AQ, ZHAO L, ZHANG LF, GU SZ, ZHAO XH. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer[J]. Experimental Cell Research, 2020, 392(2):112034.
    [16] LOPES-RAMOS C, CHEN CY, KUIJJER M, PAULSON J, SONAWANE A, FAGNY M, PLATIG J, GLASS K, QUACKENBUSH J, DEMEO D. Sex differences in gene expression and regulatory networks across 29 human tissues[J]. Cell Reports, 2020, 31(12):107795.
    [17] KFOURY N, QI ZT, PRAGER BC, WILKINSON MN, BROESTL L, BERRETT KC, MOUDGIL A, SANKARARAMAN S, CHEN XH, GERTZ J, RICH JN, MITRA RD, RUBIN JB. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma[J]. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118(16):e2017148118.
    [18] SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2019[J]. CA:A Cancer Journal for Clinicians, 2019, 69(1):7-34.
    [19] TAN YF, WANG M, CHEN ZY, WANG L, LIU XH. Inhibition of BRD4 prevents proliferation and epithelial-mesenchymal transition in renal cell carcinoma via NLRP3 inflammasome-induced pyroptosis[J]. Cell Death & Disease, 2020, 11:239.
    [20] KANAPATHIPILLAI M. Treating p53 mutant aggregation- associated cancer[J]. Cancers, 2018, 10(6):E154.
    [21] STEWART HJS, HORNE GA, BASTOW S, CHEVASSUT TJT. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1[J]. Cancer Medicine, 2013, 2(6):826-835.
    [22] WU SY, LEE AY, LAI HT, ZHANG H, CHIANG CM. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting[J]. Molecular Cell, 2013, 49(5):843-857.
    [23] DONATO E, CROCI O, SABÒ A, MULLER H, MORELLI MJ, PELIZZOLA M, CAMPANER S. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors[J]. Leukemia, 2017, 31(2):479- 490.
    [24] ABRUZZESE MP, BILOTTA MT, FIONDA C, ZINGONI A, SORIANI A, VULPIS E, BORRELLI C, ZITTI B, PETRUCCI MT, RICCIARDI MR, MOLFETTA R, PAOLINI R, SANTONI A, CIPPITELLI M. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells:role of cMYC-IRF4-miR-125b interplay[J]. Journal of Hematology & Oncology, 2016, 9(1):134.
    [25] JAENICKE LA, VON EYSS B, CARSTENSEN A, WOLF E, XU WS, GREIFENBERG AK, GEYER M, EILERS M, POPOV N. Ubiquitin-dependent turnover of MYC antagonizes MYC/PAF1C complex accumulation to drive transcriptional elongation[J]. Molecular Cell, 2016, 61(1):54-67.
    [26] ALI A, SHAFARIN J, UNNIKANNAN H, AL-JABI N, JABAL RA, BAJBOUJ K, MUHAMMAD JS, HAMAD M. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer[J]. International Journal of Biological Sciences, 2021, 17(15):4474-4492.
    [27] YANG GJ, SONG YQ, WANG WH, HAN QB, MA DL, LEUNG CH. An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells[J]. Bioorganic Chemistry, 2021, 114:105158.
    [28] ZOU Z, HUANG B, WU X, ZHANG H, QI J, BRADNER J, NAIR S, CHEN LF. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA[J]. Oncogene, 2014, 33(18):2395-2404.
    [29] TIAN B, YANG J, ZHAO YX, IVANCIUC T, SUN H, GAROFALO RP, BRASIER AR. BRD4 couples NF-κB/RelA with airway inflammation and the IRF-RIG-I amplification loop in respiratory syncytial virus infection[J]. Journal of Virology, 2017, 91(6):e00007-e00017.
    [30] YUAN XT, DAI MK, XU DW. TERT promoter mutations and GABP transcription factors in carcinogenesis:more foes than friends[J]. Cancer Letters, 2020, 493:1-9.
    [31] AKıNCıLAR SC, KHATTAR E, BOON PLS, UNAL B, FULLWOOD MJ, TERGAONKAR V. Long-range chromatin interactions drive mutant TERT promoter activation[J]. Cancer Discovery, 2016, 6(11):1276-1291.
    [32] WEEDEN CE, ASSELIN-LABAT ML. Mechanisms of DNA damage repair in adult stem cells and implications for cancer formation[J]. Biochimica et Biophysica Acta:BBA-Molecular Basis of Disease, 2018, 1864(1):89-101.
    [33] YOSHIDA K, FUJITA M. DNA damage responses that enhance resilience to replication stress[J]. Cellular and Molecular Life Sciences, 2021, 78(21/22):6763-6773.
    [34] WILSON DM 3RD, DEACON AM, DUNCTON MAJ, PELLICENA P, GEORGIADIS MM, YEH AP, ARVAI AS, MOIANI D, TAINER JA, DAS D. Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA damage response[J]. Progress in Biophysics and Molecular Biology, 2021, 163:130-142.
    [35] WANG J, WANG Y, MEI H, YIN ZY, GENG YY, ZHANG T, WU G, LIN ZY. The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21[J]. Cancer Letters, 2017, 391:141-151.
    [36] PERKHOFER L, GOUT J, ROGER E, KUDE DE ALMEIDA F, BAPTISTA SIMÕES C, WIESMÜLLER L, SEUFFERLEIN T, KLEGER A. DNA damage repair as a target in pancreatic cancer:state-of-the-art and future perspectives[J]. Gut, 2021, 70(3):606-617.
    [37] LAM FC, KONG YW, HUANG QY, HAN TLV, MAFFA AD, KASPER EM, YAFFE MB. BRD4 prevents the accumulation of R-loops and protects against transcription-replication collision events and DNA damage[J]. Nature Communications, 2020, 11:4083.
    [38] BEREI J, ECKBURG A, MILIAVSKI E, ANDERSON AD, MILLER RJ, DEIN J, GIUFFRE AM, TANG DA, DEB S, RACHERLA KS, PATEL M, VELA MS, PURI N. Potential telomere-related pharmacological targets[J]. Current Topics in Medicinal Chemistry, 2020, 20(6):458-484.
    [39] SHAY JW, WRIGHT WE. Telomeres and telomerase:three decades of progress[J]. Nature Reviews Genetics, 2019, 20(5):299-309.
    [40] LANSDORP PM. Telomeres, aging, and cancer:the big picture[J]. Blood, 2022, 139(6):813-821.
    [41] VERTECCHI E, RIZZO A, SALVATI E. Telomere targeting approaches in cancer:beyond length maintenance[J]. International Journal of Molecular Sciences, 2022, 23(7):3784.
    [42] WANG S, PIKE AM, LEE SS, STRONG MA, CONNELLY CJ, GREIDER CW. BRD4 inhibitors block telomere elongation[J]. Nucleic Acids Research, 2017, 45(14):8403-8410.
    [43] DUAN YC, GUAN YY, QIN WP, ZHAI XY, YU B, LIU HM.Targeting Brd4 for cancer therapy:inhibitors and degraders[J]. Medchemcomm, 2018, 9(11):1779-1802.
    [44] OZER HG, EL-GAMAL D, POWELL B, HING ZA, BLACHLY JS, HARRINGTON B, MITCHELL S, GRIESELHUBER NR, WILLIAMS K, LAI TH, ALINARI L, BAIOCCHI RA, BRINTON L, BASKIN E, CANNON M, BEAVER L, GOETTL VM, LUCAS DM, WOYACH JA, SAMPATH D, et al. BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor[J]. Cancer Discovery, 2018, 8(4):458-477.
    [45] ALBRECHT BK, GEHLING VS, HEWITT MC, VASWANI RG, CÔTÉ A, LEBLANC Y, NASVESCHUK CG, BELLON S, BERGERON L, CAMPBELL R, CANTONE N, COOPER MR, CUMMINGS RT, JAYARAM H, JOSHI S, MERTZ JA, NEISS A, NORMANT E, O'MEARA M, PARDO E, et al. Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials[J]. Journal of Medicinal Chemistry, 2016, 59(4):1330-1339.
    [46] ALBERT DH, GOODWIN NC, DAVIES AM, JENNY R, GEROLD F, MICHAEL B, DORRITIE KA, MARIA M, REGINA G, JONAS BA, GAUTAM B, IBRAHIM A, RIZZIERI DA, OLATOYOSI O, THOMAS P, SANJANA S, RELJA P, SHEN YU, MCDANIEL KF, KATI WM, et al. Co-clinical modeling of the activity of the BET inhibitor mivebresib (ABBV-075) in AML[J]. In Vivo:Athens, Greece, 2022, 36(4):1615-1627.
    [47] RHYASEN GW, HATTERSLEY MM, YAO Y, DULAK A, WANG WX, PETTERUTI P, DALE IL, BOIKO S, CHEUNG T, ZHANG JW, WEN SH, CASTRIOTTA L, LAWSON D, COLLINS M, BAO L, AHDESMAKI MJ, WALKER G, OʼCONNOR G, YEH TC, RABOW AA, et al. AZD5153:a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies[J]. Molecular Cancer Therapeutics, 2016, 15(11):2563-2574.
    [48] DELMORE JE, ISSA GC, LEMIEUX ME, RAHL PB, SHI JW, JACOBS HM, KASTRITIS E, GILPATRICK T, PARANAL RM, QI J, CHESI M, SCHINZEL AC, MCKEOWN MR, HEFFERNAN TP, VAKOC CR, BERGSAGEL PL, GHOBRIAL IM, RICHARDSON PG, YOUNG RA, HAHN WC, et al. BET bromodomain inhibition as a therapeutic strategy to target c-myc[J]. Cell, 2011, 146(6):904-917.
    [49] RAHL PB, LIN CY, SEILA AC, FLYNN RA, MCCUINE S, BURGE CB, SHARP PA, YOUNG RA. C-myc regulates transcriptional pause release[J]. Cell, 2010, 141(3):432-445.
    [50] TIAN Y, WANG XF, ZHAO S, LIAO X, YOUNIS MR, WANG SJ, ZHANG CN, LU GM. JQ1-loaded polydopamine nanoplatform inhibits c-MYC/programmed cell death ligand 1 to enhance photothermal therapy for triple-negative breast cancer[J]. ACS Applied Materials & Interfaces, 2019, 11(50):46626-46636.
    [51] HAJMIRZA A, EMADALI A, GAUTHIER A, CASASNOVAS O, GRESSIN R, CALLANAN MB. BET family protein BRD4:an emerging actor in NFκB signaling in inflammation and cancer[J]. Biomedicines, 2018, 6(1):E16
    [52] ERKES DA, FIELD CO, CAPPARELLI C, TIAGO M, PURWIN TJ, CHERVONEVA I, BERGER AC, HARTSOUGH EJ, VILLANUEVA J, APLIN AE. The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner[J]. Pigment Cell & Melanoma Research, 2019, 32(5):687-696.
    [53] XU K, CHEN DX, QIAN D, ZHANG SH, ZHANG Y, GUO S, MA ZQ, WANG S. AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo[J]. Biochemical and Biophysical Research Communications, 2018, 499(3):531-537.
    [54] GUO D, ZHAO YY, WANG N, YOU N, ZHU WQ, ZHANG PW, REN Q, YIN J, CHENG T, MA XT. GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML[J]. Blood, 2021, 138(6):464-479.
    [55] CHIAPPORI AA, KOLEVSKA T, SPIGEL DR, HAGER S, RARICK M, GADGEEL S, BLAIS N, VON PAWEL J, HART L, RECK M, BASSETT E, BURINGTON B, SCHILLER JH. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer[J]. Annals of Oncology, 2015, 26(2):354-362.
    [56] GATZKA MV. Targeted tumor therapy remixed-an update on the use of small-molecule drugs in combination therapies[J]. Cancers:Basel, 2018, 10(6):E155.
    [57] WANG WY, TANG YN, XIAO Q, LEE WC, CHENG B, NIU ZT, OGUZ G, FENG M, LEE PL, LI BJ, YANG ZH, CHEN YF, LAN P, WU XJ, YU Q. Stromal induction of BRD4 phosphorylation results in chromatin remodeling and BET inhibitor resistance in colorectal cancer[J]. Nature Communications, 2021, 12:4441.
    [58] LIU C, GEN Y, TANIMOTO K, MURAMATSU T, INOUE J, INAZAWA J. Concurrent targeting of MAP3K3 and BRD4 by miR-3140-3p overcomes acquired resistance to BET inhibitors in neuroblastoma cells[J]. Molecular Therapy-Nucleic Acids, 2021, 25:83-92.
    [59] ZHANG W, GE H, JIANG Y, HUANG R, WU YP, WANG DM, GUO SS, LI S, WANG YL, JIANG HB, CHENG J. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma[J]. Cancer Letters, 2020, 469:510-523.
    [60] ZHANG P, LI RD, XIAO H, LIU WZ, ZENG XY, XIE GC, YANG WC, SHI L, YIN YP, TAO KX. BRD4 inhibitor AZD5153 suppresses the proliferation of colorectal cancer cells and sensitizes the anticancer effect of PARP inhibitor[J]. International Journal of Biological Sciences, 2019, 15(9):1942-1954.
    [61] ZHANG FQ, WU ZW, CHEN P, ZHANG J, WANG T, ZHOU JP, ZHANG HB. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide[J]. Bioorganic & Medicinal Chemistry, 2020, 28(1):115228.
    [62] WANG AR, LI LL, LI MY, WANG SJ, WANG C. Case report:7-ethyl-10-hydroxycamptothecin, a DNA topoisomerase I inhibitor, performs BRD4 inhibitory activity and inhibits human leukemic cell growth[J]. Frontiers in Pharmacology, 2021, 12:664176.
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

黄千慧,丁一,谭钰雯,莫雯欣,李彤昕,黄颖而,郝文波. 溴结构域蛋白4的结构和功能及其抑制剂在肿瘤研究中的应用[J]. 生物工程学报, 2023, 39(1): 132-148

复制
分享
文章指标
  • 点击次数:1333
  • 下载次数: 1632
  • HTML阅读次数: 1729
  • 引用次数: 0
历史
  • 收稿日期:2022-05-29
  • 最后修改日期:2022-10-08
  • 在线发布日期: 2023-02-01
  • 出版日期: 2023-01-25
文章二维码
您是第6348973位访问者
生物工程学报 ® 2025 版权所有

通信地址：中国科学院微生物研究所    邮编：100101

电话：010-64807509   E-mail：cjb@im.ac.cn

技术支持：北京勤云科技发展有限公司